Hypertrophic cardiomyopathy is the most common hereditary cardiac pathology (1/1500) and is associated to heart failure, angina, arrhythmia, and sudden death. So far, no treatment has been proved effective to control this disease.
This study randomized 133 patients with hypertrophic cardiomyopathy to placebo or losartan. Primary end point was change in left ventricular (LV) mass.
A reduction of LV morphology was observed in both the placebo and the losartan groups; however, the difference between these drugs did not reach statistical significance.
Conclusion
Losartan has no effect on LV morphology in patients with hypertrophic cardiomyopathy.
3_anna_axelsson
Anna Axelsson
2014-11-19
Original title: A Randomized Trial of Losartan In Hypertrophic Cardiomyopathy – The INHERIT Trial.